MDPI and ACS Style
Afrough, A.; Atrash, S.; Paul, B.; Ouchveridze, E.; Ahmed, N.; Mahmoudjafari, Z.; Bashir, A.; Alkharabsheh, O.; Hashmi, H.; Abdallah, A.-O.
Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma. Cancers 2023, 15, 4894.
https://doi.org/10.3390/cancers15194894
AMA Style
Afrough A, Atrash S, Paul B, Ouchveridze E, Ahmed N, Mahmoudjafari Z, Bashir A, Alkharabsheh O, Hashmi H, Abdallah A-O.
Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma. Cancers. 2023; 15(19):4894.
https://doi.org/10.3390/cancers15194894
Chicago/Turabian Style
Afrough, Aimaz, Shebli Atrash, Barry Paul, Evguenia Ouchveridze, Nausheen Ahmed, Zahra Mahmoudjafari, Anam Bashir, Omar Alkharabsheh, Hamza Hashmi, and Al-Ola Abdallah.
2023. "Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma" Cancers 15, no. 19: 4894.
https://doi.org/10.3390/cancers15194894